Loading stock data…
GENB
$13.15+0.52 (+4.12%)
Market ClosedLast close May 1
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.15
Potential Upside
5%
Whystock Fair Value$13.81
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-81.72%
Volume
Today's trading volume
189,328
Recent News
H.C. Wainwright Initiates Coverage of Generate Biomedicines (GENB) With a Buy Rating
Generate Biomedicines, Inc. (NASDAQ:GENB) is one of the best low priced biotech stocks to invest in. On April 13, H.C. Wainwright initiated coverage of Generate Biomedicines, Inc. (NASDAQ:GENB) with a Buy rating, setting a $16 price target. The firm told investors in a research note that the stock has fallen over 20% even as GB-0895 advanced into […]
Generate Biomedicines (GENB) Valuation Check After Recent Share Price Weakness
Generate Biomedicines: Recent Trading Moves And Core Business Snapshot Generate Biomedicines (GENB) has seen recent share price pressure, with a 10% decline over the past week and a similar move over the past month, bringing the latest close to US$11.21. For context, the company reports revenue of US$31.893 million alongside a net loss of US$249.523 million, reflecting the costs of developing its generative biology platform and early stage pipeline of protein based therapeutics. See our...
Sector Update: Health Care Stocks Advance Late Afternoon
Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S